Quick Takeaways
- GILEAD SCIENCES, INC. filed SCHEDULE 13D for Arcellx, Inc. Common Stock, par value $0.001 (ACLX).
- Disclosed ownership: 12%.
- Date of event: 23 Feb 2026.
GILEAD SCIENCES, INC. - 23 Feb 2026 SCHEDULE 13D Report for Arcellx, Inc. Common Stock, par value $0.001 (ACLX)
- Filing Manager
- GILEAD SCIENCES, INC.
- Reporting Manager
- Gilead Sciences, Inc.
- Symbol
- ACLX
- Shares outstanding
- 58,441,765 shares
- Disclosed Ownership
- 6,720,803 shares
- Ownership
- 12%
- Form type
- SCHEDULE 13D
- Filing time
- 23 Feb 2026, 06:51:54 UTC
- Date of event
- 23 Feb 2026
- SEC
- View on sec.gov
Quoteable Key Fact
"GILEAD SCIENCES, INC. disclosed 12% ownership in Arcellx, Inc. Common Stock, par value $0.001 (ACLX) on 23 Feb 2026."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 23 Feb 2026, 06:51.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Gilead Sciences, Inc. | 12% | 6,720,803 | 6,720,803 | 0 | /s/ Andrew D. Dickinson | Andrew D. Dickinson/Chief Financial Officer | 0000882095 |